J Chem Inf Model - Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.


{ drug(1928) target(777) effect(648) }
{ bind(1733) structur(1185) ligand(1036) }
{ import(1318) role(1303) understand(862) }
{ can(981) present(881) function(850) }
{ compound(1573) activ(1297) structur(1058) }
{ gene(2352) biolog(1181) express(1162) }
{ model(2220) cell(1177) simul(1124) }
{ perform(1367) use(1326) method(1137) }
{ signal(2180) analysi(812) frequenc(800) }
{ sequenc(1873) structur(1644) protein(1328) }
{ howev(809) still(633) remain(590) }
{ detect(2391) sensit(1101) algorithm(908) }
{ state(1844) use(1261) util(961) }
{ time(1939) patient(1703) rate(768) }
{ implement(1333) system(1263) develop(1122) }
{ method(984) reconstruct(947) comput(926) }
{ risk(3053) factor(974) diseas(938) }
{ model(2341) predict(2261) use(1141) }
{ blood(1257) pressur(1144) flow(957) }
{ analysi(2126) use(1163) compon(1037) }
{ use(976) code(926) identifi(902) }
{ result(1111) use(1088) new(759) }
{ can(774) often(719) complex(702) }
{ imag(1947) propos(1133) code(1026) }
{ data(1737) use(1416) pattern(1282) }
{ imag(2675) segment(2577) method(1081) }
{ patient(2315) diseas(1263) diabet(1191) }
{ studi(2440) review(1878) systemat(933) }
{ treatment(1704) effect(941) patient(846) }
{ framework(1458) process(801) describ(734) }
{ data(3963) clinic(1234) research(1004) }
{ research(1085) discuss(1038) issu(1018) }
{ data(2317) use(1299) case(1017) }
{ medic(1828) order(1363) alert(1069) }
{ cost(1906) reduc(1198) effect(832) }
{ intervent(3218) particip(2042) group(1664) }
{ activ(1138) subject(705) human(624) }
{ structur(1116) can(940) graph(676) }
{ high(1669) rate(1365) level(1280) }
{ decis(3086) make(1611) patient(1517) }
{ method(2212) result(1239) propos(1039) }
{ model(3404) distribut(989) bayesian(671) }
{ inform(2794) health(2639) internet(1427) }
{ system(1976) rule(880) can(841) }
{ measur(2081) correl(1212) valu(896) }
{ imag(1057) registr(996) error(939) }
{ method(1219) similar(1157) match(930) }
{ featur(3375) classif(2383) classifi(1994) }
{ imag(2830) propos(1344) filter(1198) }
{ network(2748) neural(1063) input(814) }
{ take(945) account(800) differ(722) }
{ motion(1329) object(1292) video(1091) }
{ assess(1506) score(1403) qualiti(1306) }
{ surgeri(1148) surgic(1085) robot(1054) }
{ problem(2511) optim(1539) algorithm(950) }
{ error(1145) method(1030) estim(1020) }
{ chang(1828) time(1643) increas(1301) }
{ learn(2355) train(1041) set(1003) }
{ concept(1167) ontolog(924) domain(897) }
{ clinic(1479) use(1117) guidelin(835) }
{ algorithm(1844) comput(1787) effici(935) }
{ extract(1171) text(1153) clinic(932) }
{ method(1557) propos(1049) approach(1037) }
{ data(1714) softwar(1251) tool(1186) }
{ design(1359) user(1324) use(1319) }
{ control(1307) perform(991) simul(935) }
{ care(1570) inform(1187) nurs(1089) }
{ general(901) number(790) one(736) }
{ search(2224) databas(1162) retriev(909) }
{ featur(1941) imag(1645) propos(1176) }
{ case(1353) use(1143) diagnosi(1136) }
{ studi(1410) differ(1259) use(1210) }
{ perform(999) metric(946) measur(919) }
{ system(1050) medic(1026) inform(1018) }
{ visual(1396) interact(850) tool(830) }
{ studi(1119) effect(1106) posit(819) }
{ spatial(1525) area(1432) region(1030) }
{ record(1888) medic(1808) patient(1693) }
{ health(3367) inform(1360) care(1135) }
{ model(3480) simul(1196) paramet(876) }
{ monitor(1329) mobil(1314) devic(1160) }
{ ehr(2073) health(1662) electron(1139) }
{ research(1218) medic(880) student(794) }
{ patient(2837) hospit(1953) medic(668) }
{ model(2656) set(1616) predict(1553) }
{ age(1611) year(1155) adult(843) }
{ group(2977) signific(1463) compar(1072) }
{ sampl(1606) size(1419) use(1276) }
{ data(3008) multipl(1320) sourc(1022) }
{ first(2504) two(1366) second(1323) }
{ patient(1821) servic(1111) care(1106) }
{ use(2086) technolog(871) perceiv(783) }
{ health(1844) social(1437) communiti(874) }
{ cancer(2502) breast(956) screen(824) }
{ use(1733) differ(960) four(931) }
{ survey(1388) particip(1329) question(1065) }
{ estim(2440) model(1874) function(577) }
{ process(1125) use(805) approach(778) }
{ activ(1452) weight(1219) physic(1104) }
{ method(1969) cluster(1462) data(1082) }


Phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) act as critical effectors in a commonly deregulated cell signaling pathway in human cancers. The abnormal activation of the PI3K/mTOR pathway has been shown to play a role in initiation, progression, and metastasis of human tumors. Being one of the most frequently activated pathways in cancer, much effort has been directed toward inhibition of the PI3K/mTOR pathway as a novel oncology therapy. Previous work by a number of groups has revealed several selective PI3K and dual mTOR/PI3K inhibitors. However, there are few reports of therapeutic agents with a pan-PI3K/mTOR inhibitory profile within a narrow concentration range. We therefore initiated a drug discovery project with the aim of discovering dual mTOR/PI3K inhibitors which would equipotently inhibit the 4 isoforms of PI3K, a, ?, , and d, and mTOR a compelling profile for powerful blockage of the PI3K/mTOR pathway. A pharmacophore model was generated and used for designing a series of novel compounds, based on a purine scaffold, which potently inhibited mTOR and PI3Ks. These compounds contained a phenol headgroup essential for binding to the target proteins. Early efforts concentrated on finding replacements for the phenol as it was rapidly conjugated resulting in a short half-life in vivo. Compounds with a variety of headgroups were docked into the PI3Ka and mTOR ATP-binding sites, and aminopyrimidine and aminopyrazine were found to make excellent phenol replacements. Further structure guided optimization of side chains in the 8- and 9-positions of the purine resulted in potent inhibitors with good PKDM properties. As the PI3 kinases play a role in insulin signaling, it is believed that targeting mTOR selectively may give the benefit of blocking the AKT-pathway while avoiding the potential side effects associated with PI3K inhibition. As a result we designed a further series of selective mTOR kinase inhibitors. The project was successfully concluded by progressing both a dual mTOR/PI3K inhibitor, SB2343, and a selective mTOR inhibitor, SB2602, into preclinical development. SB2343 has since entered phase 1 clinical development as VS-5584.

Resumo Limpo

phosphoinositid kinas pik mammalian target rapamycin mtor act critic effector common deregul cell signal pathway human cancer abnorm activ pikmtor pathway shown play role initi progress metastasi human tumor one frequent activ pathway cancer much effort direct toward inhibit pikmtor pathway novel oncolog therapi previous work number group reveal sever select pik dual mtorpik inhibitor howev report therapeut agent panpikmtor inhibitori profil within narrow concentr rang therefor initi drug discoveri project aim discov dual mtorpik inhibitor equipot inhibit isoform pik d mtor compel profil power blockag pikmtor pathway pharmacophor model generat use design seri novel compound base purin scaffold potent inhibit mtor pik compound contain phenol headgroup essenti bind target protein earli effort concentr find replac phenol rapid conjug result short halflif vivo compound varieti headgroup dock pika mtor atpbind site aminopyrimidin aminopyrazin found make excel phenol replac structur guid optim side chain posit purin result potent inhibitor good pkdm properti pi kinas play role insulin signal believ target mtor select may give benefit block aktpathway avoid potenti side effect associ pik inhibit result design seri select mtor kinas inhibitor project success conclud progress dual mtorpik inhibitor sb select mtor inhibitor sb preclin develop sb sinc enter phase clinic develop vs

Resumos Similares

J Chem Inf Model - How does catalase release nitric oxide? A computational structure-activity relationship study. ( 0,752394054871396 )
J Chem Inf Model - Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors. ( 0,730858343949257 )
J Chem Inf Model - Computational prediction of a putative binding site on drp1: implications for antiparkinsonian therapy. ( 0,715150180088996 )
J Chem Inf Model - Structure-activity relationships in non-ligand binding pocket (non-LBP) diarylhydrazide antiandrogens. ( 0,714902895650887 )
J Chem Inf Model - Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches. ( 0,710901334860237 )
J Chem Inf Model - Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. ( 0,71013557045671 )
J Chem Inf Model - Discovery of a novel selective PPAR ligand with partial agonist binding properties by integrated in silico/in vitro work flow. ( 0,706316265377939 )
J Chem Inf Model - Key amino acid associated with acephate detoxification by Cydia pomonella carboxylesterase based on molecular dynamics with alanine scanning and site-directed mutagenesis. ( 0,698827889978037 )
J Chem Inf Model - A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. ( 0,696614237492647 )
J Chem Inf Model - Identification of the Schistosoma mansoni molecular target for the antimalarial drug artemether. ( 0,695837607719624 )
Brief. Bioinformatics - Joint analysis of miRNA and mRNA expression data. ( 0,693299711804428 )
J Chem Inf Model - Structural basis for the mutation-induced dysfunction of human CYP2J2: a computational study. ( 0,689631433619618 )
J Chem Inf Model - Predicting drug-target interactions using probabilistic matrix factorization. ( 0,686877249631709 )
J Chem Inf Model - Modeling compound-target interaction network of traditional Chinese medicines for type II diabetes mellitus: insight for polypharmacology and drug design. ( 0,685258459913205 )
Comput. Biol. Med. - Systems pharmacology-based approach for dissecting the addition and subtraction theory of traditional Chinese medicine: An example using Xiao-Chaihu-Decoction and Da-Chaihu-Decoction. ( 0,684401074440402 )
J Chem Inf Model - Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design. ( 0,683161575944207 )
J Chem Inf Model - Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis. ( 0,682568727412186 )
J Chem Inf Model - Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase. ( 0,682184291853917 )
J Chem Inf Model - Novel strategy for three-dimensional fragment-based lead discovery. ( 0,680043524178366 )
Brief. Bioinformatics - Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes. ( 0,677341074662381 )
Comput Math Methods Med - Implication of crystal water molecules in inhibitor binding at ALR2 active site. ( 0,67595163229618 )
J Chem Inf Model - Heteroaromatic p-stacking energy landscapes. ( 0,675535058677418 )
J Chem Inf Model - Molecular docking and pharmacophore filtering in the discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase. ( 0,672422223424418 )
J Chem Inf Model - Structural basis for the ?-adrenergic receptor subtype selectivity of the representative agonists and antagonists. ( 0,671628309750496 )
J Chem Inf Model - Inhibitor design strategy based on an enzyme structural flexibility: a case of bacterial MurD ligase. ( 0,67160288816842 )
J Chem Inf Model - Interactions of halichondrin B and eribulin with tubulin. ( 0,671526563763917 )
J Chem Inf Model - AutoDock4(Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins. ( 0,67121600036239 )
J Chem Inf Model - Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. ( 0,669695231869525 )
J Chem Inf Model - Computational approaches elucidate the allosteric mechanism of human aromatase inhibition: a novel possible route to Small-molecule regulation of CYP450s activities? ( 0,668839065486662 )
J Chem Inf Model - Lipoic acid and dihydrolipoic acid. A comprehensive theoretical study of their antioxidant activity supported by available experimental kinetic data. ( 0,668702189401293 )
J Chem Inf Model - Structural modeling of HCV NS3/4A serine protease drug-resistance mutations using end-point continuum solvation and side-chain flexibility calculations. ( 0,667557202058252 )
J Chem Inf Model - Chemical genomics approach for GPCR-ligand interaction prediction and extraction of ligand binding determinants. ( 0,665678241539777 )
J Chem Inf Model - Quantum mechanical/molecular mechanical study of catalytic mechanism and role of key residues in methylation reactions catalyzed by dimethylxanthine methyltransferase in caffeine biosynthesis. ( 0,66434417203825 )
J Chem Inf Model - Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies. ( 0,663341108703019 )
J Chem Inf Model - Detailed mechanism of squalene epoxidase inhibition by terbinafine. ( 0,663278072151883 )
J Chem Inf Model - Addressing selective polypharmacology of antipsychotic drugs targeting the bioaminergic receptors through receptor dynamic conformational ensembles. ( 0,663031394616755 )
J Chem Inf Model - Exploring the desumoylation process of SENP1: a study combined MD simulations with QM/MM calculations on SENP1-SUMO1-RanGAP1. ( 0,660824278275335 )
J Integr Bioinform - Widespread recruitment of ancient domain structures in modern enzymes during metabolic evolution. ( 0,658932283563593 )
J Chem Inf Model - A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling. ( 0,654081135654756 )
J Chem Inf Model - Residue preference mapping of ligand fragments in the Protein Data Bank. ( 0,653705611296256 )
J Chem Inf Model - Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase. ( 0,653224696379732 )
J Chem Inf Model - Characterizing binding of small molecules. II. Evaluating the potency of small molecules to combat resistance based on docking structures. ( 0,653210213095535 )
J Chem Inf Model - Minor groove binders and drugs targeting proteins cover complementary regions in chemical shape space. ( 0,652612791546634 )
J Chem Inf Model - The hydrogen bond environments of 1H-tetrazole and tetrazolate rings: the structural basis for tetrazole-carboxylic acid bioisosterism. ( 0,652281325200064 )
J Chem Inf Model - GES polypharmacology fingerprints: a novel approach for drug repositioning. ( 0,652041732006315 )
J Chem Inf Model - Elucidating substrate promiscuity in the human cytochrome 3A4. ( 0,651478371545571 )
J Chem Inf Model - Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. ( 0,650818943733157 )
Brief. Bioinformatics - A reversed framework for the identification of microRNA-target pairs in plants. ( 0,650257364311011 )
Comput Biol Chem - In silico study of anti-carcinogenic lysyl oxidase-like 2 inhibitors. ( 0,649500867980401 )
Brief. Bioinformatics - Motif discovery and transcription factor binding sites before and after the next-generation sequencing era. ( 0,649116769628033 )
J Chem Inf Model - EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors. ( 0,647521733554893 )
J Chem Inf Model - Computational modeling of an epidermal growth factor receptor single-mutation resistance to cetuximab in colorectal cancer treatment. ( 0,645994559655 )
J Chem Inf Model - Structural insights into trapping and dissociation of small molecules in K channels. ( 0,645626451355488 )
J Chem Inf Model - Identification of small-molecule inhibitors against human leukocyte antigen-death receptor 4 (HLA-DR4) through a comprehensive strategy. ( 0,644631603042139 )
Wiley Interdiscip Rev Syst Biol Med - Heparan sulfate proteoglycans in healthy and diseased systems. ( 0,643080516859985 )
J Am Med Inform Assoc - Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning. ( 0,640079375432626 )
J Chem Inf Model - 2D SMARTCyp reactivity-based site of metabolism prediction for major drug-metabolizing cytochrome P450 enzymes. ( 0,63888607455837 )
J Chem Inf Model - Structurally conserved binding sites of hemagglutinin as targets for influenza drug and vaccine development. ( 0,637125316895109 )
J Chem Inf Model - Scoring function based approach for locating binding sites and understanding recognition mechanism of protein-DNA complexes. ( 0,636879483775927 )
J Chem Inf Model - Top leads for swine influenza A/H1N1 virus revealed by steered molecular dynamics approach. ( 0,636559384363753 )
J Chem Inf Model - Identification of a new binding site in E. coli FabH using Molecular dynamics simulations: validation by computational alanine mutagenesis and docking studies. ( 0,636403935181286 )
J Chem Inf Model - Virtual screening of PRK1 inhibitors: ensemble docking, rescoring using binding free energy calculation and QSAR model development. ( 0,636378849497437 )
J Chem Inf Model - Combining dyad protonation and active site plasticity in BACE-1 structure-based drug design. ( 0,636249731566295 )
J Chem Inf Model - Molecular modeling of exquisitely selective c-Met inhibitors through 3D-QSAR and molecular dynamics simulations. ( 0,635922456558147 )
J Chem Inf Model - Structure-based drug design of diphenyl a-aminoalkylphosphonates as prostate-specific antigen antagonists. ( 0,634664162674204 )
J Chem Inf Model - ?-Amyloid and neprilysin computational studies identify critical residues implicated in binding specificity. ( 0,633574964045001 )
J Chem Inf Model - In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE. ( 0,632484654809888 )
J Chem Inf Model - A pragmatic approach using first-principle methods to address site of metabolism with implications for reactive metabolite formation. ( 0,632369501218882 )
J Chem Inf Model - Potency prediction of ?-secretase (BACE-1) inhibitors using density functional methods. ( 0,631654685604981 )
J Chem Inf Model - Identification of sumoylation inhibitors targeting a predicted pocket in Ubc9. ( 0,629386378446675 )
J Chem Inf Model - Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome. ( 0,629141134648717 )
J Chem Inf Model - Docking ligands into flexible and solvated macromolecules. 6. Development and application to the docking of HDACs and other zinc metalloenzymes inhibitors. ( 0,628712085507886 )
J Chem Inf Model - Hot spots and transient pockets: predicting the determinants of small-molecule binding to a protein-protein interface. ( 0,627808301537507 )
J Chem Inf Model - Molecular modeling of p38a mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations. ( 0,627250101344142 )
J Chem Inf Model - Fighting obesity with a sugar-based library: discovery of novel MCH-1R antagonists by a new computational-VAST approach for exploration of GPCR binding sites. ( 0,626503390969574 )
J Chem Inf Model - Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol. ( 0,625814204814999 )
J Chem Inf Model - Exploring inhibitor release pathways in histone deacetylases using random acceleration molecular dynamics simulations. ( 0,62530743532329 )
J Chem Inf Model - Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs. ( 0,625291768251527 )
J Chem Inf Model - Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy. ( 0,623427086472482 )
J Chem Inf Model - Halogen bond: its role beyond drug-target binding affinity for drug discovery and development. ( 0,622516030502591 )
J Chem Inf Model - Insights into the conformational switching mechanism of the human vascular endothelial growth factor receptor type 2 kinase domain. ( 0,622129454392173 )
J Chem Inf Model - Novel inhibitors of trihydroxynaphthalene reductase with antifungal activity identified by ligand-based and structure-based virtual screening. ( 0,621635738694464 )
J Chem Inf Model - Computer-aided drug design of falcipain inhibitors: virtual screening, structure-activity relationships, hydration site thermodynamics, and reactivity analysis. ( 0,620979738008704 )
J Chem Inf Model - Structure-based design technology contour and its application to the design of renin inhibitors. ( 0,61977418772493 )
J Chem Inf Model - A computational approach to design and evaluate enzymatic reaction pathways: application to 1-butanol production from pyruvate. ( 0,61964800585828 )
J Chem Inf Model - Impact of resistance mutations on inhibitor binding to HIV-1 integrase. ( 0,617955646852953 )
J Chem Inf Model - Design of linear ligands for selective separation using a genetic algorithm applied to molecular architecture. ( 0,617601401549429 )
Comput. Biol. Med. - Structural modeling and simulation studies of human cyclooxygenase (COX) isozymes with selected terpenes: implications in drug designing and development. ( 0,617416773710086 )
Wiley Interdiscip Rev Syst Biol Med - Large scale molecular simulations of nanotoxicity. ( 0,615677826661401 )
J Chem Inf Model - Molecular modeling and molecular dynamics simulation studies of the GSK3?/ATP/substrate complex: understanding the unique P+4 primed phosphorylation specificity for GSK3? substrates. ( 0,615053838453517 )
Comput Biol Chem - Communication between the active site and the allosteric site in class A beta-lactamases. ( 0,614719958017262 )
J Chem Inf Model - CRDOCK: an ultrafast multipurpose protein-ligand docking tool. ( 0,613310659761745 )
J Chem Inf Model - Autoinhibitory mechanism for the mutation-induced impaired FGF9 signaling. ( 0,613051948818714 )
Wiley Interdiscip Rev Syst Biol Med - Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. ( 0,61289303695785 )
J Chem Inf Model - Influence of the membrane lipophilic environment on the structure and on the substrate access/egress routes of the human aromatase enzyme. A computational study. ( 0,612682749245855 )
J Chem Inf Model - Chemogenomics approaches to rationalizing the mode-of-action of traditional Chinese and Ayurvedic medicines. ( 0,612289136717555 )
J Chem Inf Model - Drug effect prediction by polypharmacology-based interaction profiling. ( 0,612237907771751 )
J Chem Inf Model - Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics. ( 0,610951343001475 )
Brief. Bioinformatics - Data mining the human gut microbiota for therapeutic targets. ( 0,609567851665477 )
Comput. Biol. Med. - The computational model to predict accurately inhibitory activity for inhibitors towards CYP3A4. ( 0,609368491806194 )